Ovid Therapeutics Inc. Increase (Decrease) in Deferred Revenue
Ovid Therapeutics Inc. (OVID) reported Increase (Decrease) in Deferred Revenue of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-13
- Ovid Therapeutics Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- Ovid Therapeutics Inc. increase (decrease) in deferred revenue for the quarter ending 2024-09-30 was $0.00.
- Ovid Therapeutics Inc. increase (decrease) in deferred revenue for the quarter ending 2022-03-31 was $0.00.
- Ovid Therapeutics Inc. increase (decrease) in deferred revenue for the quarter ending 2021-12-31 was $0.00.
- Ovid Therapeutics Inc. increase (decrease) in deferred revenue for fiscal 2021 was -$12.38M, a 200.00% decline from fiscal 2020.
- Ovid Therapeutics Inc. increase (decrease) in deferred revenue for fiscal 2020 was $12.38M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $718.00K 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $718.00K 10-Q · filed 2026-08-13 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-05-10 | $0.00 derived: sum of 3 quarters · filed 2022-05-10 | $0.00 derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | -$12.38M 10-K · filed 2022-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | -$12.38M 10-Q · filed 2021-11-10 | -$13.09M derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$12.38M 10-Q · filed 2021-08-16 | -$13.09M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2021-03-31 | -$12.38M 10-Q · filed 2022-05-10 | -$13.09M derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2020-12-31 | -$703.19K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $12.38M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $13.09M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |